CARLSBAD, Calif.--(BUSINESS WIRE)--Jan. 10, 2006--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced that its subsidiary, Invitrogen Federal Systems, was awarded a $970K Technical Assistance Agreement by the U.S. Department of Defense to produce and validate protein microarrays to biothreat agents. This work will be conducted under the direction of Dr. James Meegan, Senior Director of Research & Development at Invitrogen, and is designed to support the U.S. Army Medical Research and Materiel Command’s (USAMRMC) mission to provide solutions to medical problems of importance to the American war fighter at home and abroad. Dr. Robert Ulrich, Ph.D. is responsible for scientific and technical conduct of this project at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
